<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The management of patients with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> (HCM) and refractory symptoms due to massive <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> and severe diastolic dysfunction represents a real challenge for the clinical cardiologist </plain></SENT>
<SENT sid="1" pm="."><plain>Such patients often require novel therapeutic approaches, both invasive and pharmacological, involving multidisciplinary teamwork; however, the implementation of potentially viable treatment options is hindered by lack of disease-specific evidence </plain></SENT>
<SENT sid="2" pm="."><plain>We report the case of a young woman with severe HCM and restrictive <z:mp ids='MP_0001532'>physiology</z:mp>, who underwent extensive myectomy via the transaortic and transapical approach, followed by biventricular pacing for cardiac resynchronization, with significant but incomplete symptomatic improvement </plain></SENT>
<SENT sid="3" pm="."><plain>The subsequent introduction of ranolazine, based on promising preclinical data, has led to an excellent final result </plain></SENT>
<SENT sid="4" pm="."><plain>An ongoing randomized clinical trial is currently testing the efficacy of ranolazine in symptomatic HCM </plain></SENT>
</text></document>